TheEdgeResearch
Home / Stocks / ELVAF

EvoNext Holdings S.A. (ELVAF)

OTC Healthcare Biotechnology
$2.15 ▲ +0.00%
Market Cap
$15.5M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.05
52-Wk Range
0.9-2.15
CEO
Gerhard Lobmaier
Country
CH
Currency
USD

EvoNext Holdings S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Reinach, BL, CH. The stock last traded at $2.15, up 0.00% on the session, giving a market capitalisation of $15.5M. On trailing twelve-month figures it carries a trailing P/E of -23.01, a net margin of 0.0%. Its beta of -0.05 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-23.01
Price / Sales
0.00
Price / Book
2.52
EV / EBITDA
-25.56
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
8.31
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
49
IPO date
2021-01-08
Headquarters
Reinach, BL, CH
About EvoNext Holdings S.A.

EvoNext Holdings SA focuses on the discovery, refinement, and market introduction of innovative components for nutritional, healthcare, and general wellness applications. This enterprise was established in 2004 by Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith, and maintains its primary base of operations in Reinach, Switzerland.

Comparable companies

EvoNext Holdings S.A. is most often compared with the following Healthcare names:

AVCNFBBIXFCLYYFFNCHHSITFMRESPOSCRVXCFSPHRFVYYRF
More research on ELVAF
ELVAF technical analysis ELVAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →